Aeras Global TB Vaccine Base to initiate clinical trial of new investigational vaccine Modernized BCG vaccine made to assault TB at multiple stagesAt a global gathering of TB vaccine researchers in Tallinn today, the Aeras Global TB Vaccine Basis announced it will initiate a clinical trial of an investigational live recombinant tuberculosis vaccine to end up being led by researchers at Saint Louis University in St. Louis, Missouri, USA. The announcement was made at the next Global Discussion board on TB Vaccine Advancement online . Building on more than a 10 years of global scientific research, Aeras scientists have engineered a new investigational vaccine, known as AERAS-422, which will undergo clinical trials to judge its properties for interrupting TB at all phases of infection, including initial infection, latency and reactivation.
We are gratified and encouraged by this strong show of support from a superb band of leading lifestyle sciences investors, stated Tom van Haarlem, MD, President and CEO of Aerie. Glaucoma is certainly still the next leading cause of visible disability and blindness in the world today. We are worked up about the prospect of Aerie’s compounds to offer multiple, differentiated and improved treatment plans for millions of patients experiencing this widespread, degenerative disease. With the financing, Dennis Henner, PhD, Controlling Director at Clarus Ventures, joined Aerie’s Plank of Directors. Related StoriesAllergan completes acquisition of AqueSysEnvisia's ENV515 meets main efficacy endpoint in phase 2a glaucoma trialAllergan enters into contract to acquire Aquesys and its XEN45 plan The more we learn about the unique, clinical great things about AR-12286, the more enthusiastic we are regarding its prospects as an differentiated and important glaucoma treatment, both seeing that monotherapy and in combination with existing glaucoma medications, said Dr.